louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00984022: Aquacel Versus Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage
Official title: Aquacel vs. Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage: A Randomized Control Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Abscess
Cellulitis
Keywords: abscess
MRSA
Aquacel dressing
Iodoform dressing
Lead sponsor: Valleywise Health
Sponsor class: OTHER
First posted: 2009-09-24
Enrollment: 92
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Aquacel vs. Iodoform Gauze
Primary purpose: TREATMENT

Brief summary: This study compares Aquacel against routine Iodoform packing for packing abscess cavities after incision and drainage. It is hypothesized that Aquacel will produce speedier healing of the abscess.

Detailed description: The large increase in the incidence of skin and soft tissue infections cause by methicillin resistant staphylococcus aureus (MRSA) has produced a corresponding increase in the number of ED patients presenting with abscesses that require incision and drainage. This study compares Aquacel against routine Iodoform packing for packing abscess cavities after incision and drainage. It is hypothesized that Aquacel will produce speedier healing of the abscess. More effective abscess healing will reduce the need for oral antibiotic coverage, which will in turn reduce the potential for drug resistance caused by indiscriminate use of oral antibiotics.

Eligibility criteria: Inclusion Criteria:

* presenting to Maricopa Medical Center ED with cutaneous abscess requiring incision and drainage

Exclusion Criteria:

* known sensitivity to Aquacel
* pregnant, nursing, or expecting to become pregnant
* incarcerated patient
* prior treatment of same abscess with incision and drainage
* multiple abscesses
* immunodeficiency
* facial abscess
* suspected osteomyelitis or septic arthritis
* diabetic foot, decubitis, or ischaemic ulcers
* unable to provide informed consent or assent

Primary outcomes:
measure: Number of Participants Who Experienced a 30% or Greater Reduction in Surface Area of Abscess
timeFrame: 2 weeks
Secondary outcomes:
measure: Change in Patient Rating of Pain
timeFrame: Baseline and 2 weeks
measure: Number of Participants Who Experienced a 30% or Greater Reduction in Surface Area of Cellulitis.
timeFrame: 2 weeks
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Maricopa Integrated Health System
state: Arizona
Study officials:
affiliation: District Medical Group
name: Madhumita Sinha, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05931822: Silver Diamine Fluoride Modified Restoration In Treating Hypomineralized First Permanent Molar.
Official title: Quantitative Evaluation of Silver Diamine Fluoride Modified Restoration In Treating Hypomineralized First Permanent Molar In A Group Of Children"-A Clinical Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Molar Incisor Hypomineralization
Keywords: MIH, silver diamine fluoride, children, glass ionomer
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2023-07-05
Enrollment: 42
Sex: ALL
Minimum age (years): 6
Maximum age (years): 9
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A randomized clinical trial to compare silver modified glass ionomer restorations to non silver glass ionomer restorations in hypo-mineralized first permanent molars in children and to measure the amount of wear of restoration in both groups along with detecting changes in hypersensitivity in hypomineralized molars in both groups after one year follow up.


Eligibility criteria: Inclusion Criteria:

* Bilateral first permanent molars affected with molar incisor hypomineralization and with the same ICDAS II score.
* Both chosen molars should be of the same degree of MIH severity.

Exclusion Criteria:

* signs and symptoms of irreversible pulpitis or pulp necrosis.

Primary outcomes:
measure: Measuring surface wear using CAD-CAM software program
timeFrame: after 1 year
measure: Restoration Survival evaluation using the Atraumatic Restorative Treatment(ART) criteria
timeFrame: 1 year
Secondary outcomes:
measure: Tooth hypersensitivity was evaluated with Schiff cold air sensitivity scale (SCASS)
timeFrame: after 1 year
Other outcomes:
Locations:
city: Mansoura
country: Egypt
facility: Mansoura University
state: Dakaleya
Study officials:
affiliation: Mansoura University, Mansoura, Egypt
name: Abeer Abd Elatiif, professor
role: STUDY_DIRECTOR
References:
Clinical trial NCT03196622: Validation of a Screening Test for Sarcopenia in Older People
Official title: Validation of a Screening Test of Sarcopenia in the Elderly People at Hospital and in Retirement Houses
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Sarcopenia
Keywords: Sarcopenia
Elderly people
Hospitalization
Lead sponsor: University Hospital, Clermont-Ferrand
Sponsor class: OTHER
Collaborators: name: Nutriset
First posted: 2017-06-23
Enrollment: 1300
Sex: ALL
Minimum age (years): 75
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Identify the threshold which the handgrip strenght can be used as a screening test of sarcopenia.

Handgrip strenght can be used in daily clinical practice to screen patients having sarcopenia to improve treatment and quality of life.

Detailed description: A cross-sectional multicentre study will be performed in hospital and retirement houses on patients ages 75 years old or more.

Eligibility criteria: Inclusion Criteria:

* ≥ 75 years old

Exclusion Criteria:

* Palliative care,
* Protection of vulnerable adults

Primary outcomes:
measure: Handgrip test could be used as a screening test of sarcopenia
timeFrame: at day 1
Secondary outcomes:
Other outcomes:
Locations:
city: Clermont-Ferrand
country: France
facility: CHU de Clermont-Ferrand
state: Auvergne
Study officials:
affiliation: CHU de Clermont-Ferrand
name: Marie BLANQUET
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03080922: High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML
Official title: Treatment of Relapsed/Refractory Acute Myeloblastic Leukemia(AML) by Infusion of Donor High Dose Allogeneic Mismatched Hematopoietic Stem Cells After Chemotherapy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Leukemia, Myeloid
Keywords: Acute Myeloid Leukemia
Relapsed
Refractory
hematopoietic stem cell
Lead sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Sponsor class: OTHER
First posted: 2017-03-15
Enrollment: 10
Sex: ALL
Minimum age (years): 15
Maximum age (years): 85
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and efficiency of high dose allogeneic mismatched hematopoietic stem cells infusions after normal chemotherapy in patients with relapsed/refractory acute myeloid leukemia（AML）.

Detailed description: The relapsed/refractory AML patients will receive IA/DA/MA(I,Idamycin，D，Daunorubicin，M，Mitoxantrone，A，cytosine arabinoside) chemotherapy followed by infusion of high dose allogeneic mismatched hematopoietic stem cells.

no graft-versus-host disease (GVHD) prevention will be conducted before transplantation. Cytokine storm,GVHD snd donor graft will be detected post-transplantation.

Eligibility criteria: Inclusion Criteria:

* Patient with relapsed and/or refractory AML
* Estimated life expectancy ≥ 12 weeks (according to investigator's judgment)
* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

Exclusion Criteria:

* Previous treatment with investigational gene or cell therapy medicine products
* Any uncontrolled active medical disorder that would preclude participation as outlined

Primary outcomes:
measure: complete remission rate
timeFrame: 2 months
Secondary outcomes:
measure: Disease-free survival
timeFrame: 2 years
measure: Overall survival
timeFrame: 2 years
measure: donor graft rate
timeFrame: 6 months
measure: Occurrence of study related adverse events
timeFrame: 6 months
Other outcomes:
Locations:
city: Beijing
country: China
facility: Affiliated Hospital of Academy of Military Medical Sciences ,
state: Beijing
Study officials:
affiliation: Affiliated Hospital of Academy of Military Medical Sciences
name: HUISHENG AI
role: STUDY_CHAIR
References:
Clinical trial NCT01420822: Special Drug Use Investigation for ALLERMIST (Long Term)
Official title: Special Drug Use Investigation for ALLERMIST (Long Term)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Rhinitis
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2011-08-22
Enrollment: 500
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The target subjects shall be those who with allergic rhinitis for which the indication of ALLERMIST has been approved and who are using ALLERMIST for the first time and also who are expected to use ALLERMIST for long-term (1 year).

Brief summary: This post-marketing surveillance study is to investigate possible problems or questions in safety and efficacy of ALLERMIST Nasal Spray for long-term use in Japanese subjects with allergic rhinitis under the conditions of actual practical use.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of allergic rhinitis
* Use ALLERMIST for the first time
* Expected to use ALLERMIST for long-term (1 year).

Exclusion Criteria:

* Subjects with infection which fluticasone is not effective
* Subjects with deep mycosis
* Subjects with hypersensitivity to fluticasone

Primary outcomes:
measure: The number of incidence of adverse events in Japanese subjects treated with ALLERMIST Nasal Spray for long-term use
timeFrame: One year
measure: Efficacy evaluation based on the subjective/objective symptom progresses in the period from the start of Allermist treatment to the end of the observation period
timeFrame: One year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References:
Clinical trial NCT02267122: Total Occlusive Ionic Silver-containing Dressing vs Mupirocin Ointment Application vs Conventional Dressing in Elective Colorectal Surgery: Effect on Incisional Surgical Site Infection
Official title: Total Occlusive Ionic Silver-containing Dressing vs Mupirocin Ointment Application vs Conventional Dressing in Elective Colorectal Surgery: Effect on Incisional Surgical Site Infection
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Incisional Surgical Site Infections
Lead sponsor: Hospital General Universitario Elche
Sponsor class: OTHER
First posted: 2014-10-17
Enrollment: 147
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The patients were randomized into 3 groups: those patients undergoing a ionic silver-containing dressing (ISD) (Group 1), those undergoing a Mupirocin ointment application (MOA) (Group 2) and those using a conventional dressing (Group 3) in the surgical wound after finishing an elective colorectal surgery.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of colorectal neoplasms and plans to undergo an elective surgery with curative aims.
* Open surgical approach

Exclusion Criteria:

* Anastomotic leak
* Mortality
* Lost to follow-up

Primary outcomes:
measure: Incisional Surgical site infection
timeFrame: 30 postoperative days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Ruiz-Tovar J, Llavero C, Morales V, Gamallo C. Total Occlusive Ionic Silver-Containing Dressing vs Mupirocin Ointment Application vs Conventional Dressing in Elective Colorectal Surgery: Effect on Incisional Surgical Site Infection. J Am Coll Surg. 2015 Aug;221(2):424-9. doi: 10.1016/j.jamcollsurg.2015.04.019. Epub 2015 Apr 28.
Clinical trial NCT02247622: Telomere Length and Other Parameters of Telomere Dysfunction in PSC and Colitis
Official title: Primary Sclerosing Cholangitis Telomere Length
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Primary Sclerosing Cholangitis
Inflammatory Bowel Disease
Keywords: telomeres
PSC
Lead sponsor: Meir Medical Center
Sponsor class: OTHER
First posted: 2014-09-25
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with primary sclerosing cholangitis and inflammatory bowel disease

Brief summary: PSC is a chronic cholestatic disorder. The investigators intend to study some telomere parameters and telomere length in order to predict a premalignant state.

Detailed description: Primary sclerosing cholangitis (PSC) and colitis are chronic inflammatory disorders with malignant potential. Telomerase is an enzyme complex that lengthens telomeres and has enhanced expression in numerous malignancies. In this study, we evaluated the telomerase gene copy number, telomere length, cells in senescence, aneuploidy and additional parameters of telomere dysfunction from peripheral blood lymphocytes of patients.

Eligibility criteria: Inclusion Criteria:

* informed consent
* documented PSC and inflammatory bowel disease

Exclusion Criteria:

* under 18 years, above 80 y
* known active malignancy
* decompensated cirrhosis
* patients who cannot sign informed consent

Primary outcomes:
measure: Telomere length
timeFrame: 1.5 years
Secondary outcomes:
measure: number of cells with increased telomerase RNA component (TERC) expression
timeFrame: 1.5 years
Other outcomes:
Locations:
city: Kfar Saba
country: Israel
facility: Meir Medical Center
Study officials:
References:
citation: Laish I, Katz H, Stein A, Liberman M, Naftali T, Kitay-Cohen Y, Biron-Shental T, Konikoff FM, Amiel A. Telomere dysfunction in peripheral blood lymphocytes from patients with primary sclerosing cholangitis and inflammatory bowel disease. Dig Liver Dis. 2015 Sep;47(9):790-6. doi: 10.1016/j.dld.2015.05.002. Epub 2015 May 13.
Clinical trial NCT03483922: HCC Screening Using DNA Methylation Changes in ctDNA
Official title: Clinical Trials on Detection of Hepatocellular Carcinoma With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC and T Cells
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hepatocellular Carcinoma
Lead sponsor: HKGepitherapeutics
Sponsor class: INDUSTRY
Collaborators: name: International Centre for Diarrhoeal Disease Research, Bangladesh
First posted: 2018-03-30
Enrollment: 403
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: HCC staging will be diagnosed according to EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. The patients will be divided into four groups, including Stage 0 (1) (n=100), stage A (2) (n=100), stage B (3) (n=100) and stage C+D (4) (n=100). As controls we will recruit chronic hepatitis B (n=100), which diagnose will be confirmed using AASLD practice guideline for chronic Hepatitis B, and healthy sex and age matched controls (n=100).

Brief summary: Hepatocellular Carcinoma (HCC) is the fifth most common cancer world-wide. It is particularly prevalent in Asia, and its occurrence is highest in areas where hepatitis B is prevalent, indicating a possible causal relationship. Follow up of high-risk populations such as chronic hepatitis patients and early diagnosis of transitions from chronic hepatitis to HCC would improve cure rates. In most cases HCC is detected late resulting in increased mortality and morbidity.

The purpose of this study is to develop and test non-invasive biomarkers based on methylation changes in PBMC and circulated tumor DNA in hepatocellular carcinomas patients.


Eligibility criteria: Inclusion Criteria:

* Confirmed diagnosis of HCC by EASL-EORTC guidelines
* Confirmed hepatitis B diagnosis for HepB patients using AASLD practice guidelines.

Exclusion Criteria for HCC:

* Cirrhosis, any other known inflammatory disease (bacterial or viral infection with the exception of hepatitis B or C, diabetes, asthma, autoimmune disease, active thyroid disease) which could alter T cells and monocytes characteristics
* Other cancers.

Exclusion Criteria for HepB:

* Diagnosis of HCC or any other cancer.

Exclusion Criteria for Healthy Controls:

* Any known inflammatory or infectious disease including HepB and HepC
* Chronic diseases,
* Cancer
* Medications or drug use

Primary outcomes:
measure: Calculation of M Scores and HCC Probability Scores
timeFrame: 6 months to 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Dhaka
country: Bangladesh
facility: Infectious Diseases Division
Study officials:
affiliation: nternational Centre for Diarrhoeal Disease Research
name: Wasif Ali Khan, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04261322: Rabies Treatment by Exposure of Patient to X-Ray
Official title: Effect of X-ray on Rabies Virus in Vivo
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: Treatment of Rabies
Lead sponsor: National Institute For Research On Endemic Diseases And Liver, Egypt
Sponsor class: OTHER_GOV
First posted: 2020-02-07
Enrollment: 4
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: x-ray has been proven to kill Rabies virus in vitro, so the investigators can use it in treatment of rabies infected patients.

Detailed description: x-ray has been proven to kill Rabies virus in vitro, so the investigators can use it in treatment of rabies infected patients.

this can be done by exposure of infected , manifested patient who didn't receive prophylaxis or delayed in receiving immunoglobulins .

also can be applied to patients who have the injury in upper body near the CNS..

it's just an idea and the investigators need help to approve its effect and the investigators believe it will really work and give a new, rapid , cheap and very effective treatment to a 100% fatal disease..

the investigator also predict good results when x ray applied to some localized infections beside its current lines of treatment..

Eligibility criteria: Inclusion Criteria:

* patient bitten by rabid animal with signs and symptoms

Exclusion Criteria:

* bitten by non rabid animal

Primary outcomes:
measure: the number of rabies infected, symptomatic patients who survived after x-ray exposure
timeFrame: 7 month
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02272322: Transvaginal Treatment of Symptomatic Cystocele Grade II-III
Official title: Transvaginal Treatment of Symptomatic Cystocele Grade II-III Using Cousin Biomesh Soft Prolaps or Allium Medical Endofast Reliant
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Cystocele
Keywords: Anterior prolapse
Lead sponsor: Regionaal Ziekenhuis Heilig Hart Tienen
Sponsor class: OTHER
First posted: 2014-10-22
Enrollment: 100
Sex: FEMALE
Minimum age (years): 40
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with symptomatic anterior prolapse

Brief summary: This observational study will evaluate treatment of symptomatic cystocele grade II-III with Cousin Biomesh and Allium Medical Endofast Reliant. Data about 100 patients will be collected. Follow-up till 3 years after the procedure. Primary endpoint is absence of recurrence.


Eligibility criteria: Inclusion Criteria:

* Patient is a woman
* Patient is between 40 and 90 years old
* Patient has to sign the informed consent form prior to the procedure
* Patient has to agree with the scheduled follow-up visits on month 1, month 6, year 1, year 2 and year 3
* Patient has symptomatic anterior prolapse

Exclusion Criteria:

* Recurrence cystocele
* Patient is pregnant
* Patient has a wish to become pregnant
* Patient is taking Plavix, Sintrom, Marcoumar, Marevan, Brilique, Efient, Ticlid, Xarelto, Eliquis or Pradaxa. If intake is stopped prior to procedure, patient is allowed to be included.
* Patient is taking LMWH in a dose of more than 40 mg/day
* Patient has a life expectancy \< 1 year
* Patient has a known connective tissue disease
* Patient has a history of surgery of the anterior vaginal wall or pelvis
* A scheduled hysterectomy during the index-procedure

Primary outcomes:
measure: Absence of recurrence
timeFrame: 3 years
Secondary outcomes:
measure: Technical success
timeFrame: day 1
measure: Procedural success
timeFrame: 30 days
measure: Peroperative complications
timeFrame: day 1
measure: Postoperative complications
timeFrame: 3 years
measure: Quality of life
timeFrame: 3 years
Other outcomes:
Locations:
city: Tienen
country: Belgium
facility: RZ Heilig Hart Tienen
state: Vlaams-Brabant
Study officials:
affiliation: RZ Heilig Hart Tienen
name: Koen Slabbaert, MD
role: PRINCIPAL_INVESTIGATOR
References: